Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
HighPeak Energy, Inc. Announces 2026 Third Quarter Earnings Release and Conference Call Dates
-
Healthcare Triangle Enters Neurotechnology AI Devices and Solutions for Southeast Asia
-
Bio-Thera Announces NMPA Approval of BAT2306, the First Secukinumab Biosimilar Approved in China
-
Alliance Resource Partners, L.P. Reports Third Quarter 2026 Financial and Operating Results; Declares Quarterly Cash Distribution of $0.60 Per Unit; and Updates Guidance
-
First Farmers and Merchants Corporation Reports Third Quarter Net Income Up 12.7% to $5.5 Million
-
DENARIUS METALS ANNOUNCES FURTHER RAMP UP IN ITS THIRD QUARTER AND FIRST NINE MONTHS 2026 PRODUCTION RESULTS FROM ITS ZANCUDO PROJECT IN COLOMBIA
-
Turo and Tesla Debut Industry-First Self-Driving Rental Experience
-
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
-
Walmart Unwraps Three Major Holiday Shopping Events, Bringing Big Savings on Gifts and Seasonal Favorites
-
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
-
Pacific Power Wins 2026 AEIC Achievement Award for Supporting Energy Affordability with Bidgely UtilityAI
-
OIAAA and uReport Announce Landmark Partnership to Transform High School Sports Coverage Across Ohio
-
Latino Broadcasters, Artists, Digital Creators witness St. Jude impact at Promesa y Esperanza seminar
-
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
-
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
-
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
-
RyCarma Announces First Patient Dosed in Phase 2 Clinical Trial of Surlorian for the Treatment of RYR1-Related Myopathy
-
VETARYS Announces Partnership with Antigenesis Biologics to Develop a Combination Immunotherapy to Treat Canine Cancers
-
Genius Sports to Announce Third Quarter 2026 Results on November 5
-
Braemar Unveils Highly Qualified Independent Board Slate for Company’s New Chapter
-
DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds
-
FedEx Names Jamere Jackson as Executive Vice President and Chief Financial Officer
-
Jack in the Box Announces Fourth Quarter and Full-Year 2026 Earnings Webcast
-
D-Wave Quantum to Participate in Upcoming Investor Conferences
-
Builders FirstSource Annual Charity Event Raises $1.6 Million for Blood Cancer United
-
Envision Founder and CEO Lei Zhang Named Sustainability Trailblazer at Reuters Global Sustainability Awards 2026
-
Children and Adults Facing Cancer Gain More Treatment Options in Central Florida with MEVION S250-FIT™ Proton Therapy System at AdventHealth
-
Gildan Completes Sale of HanesBrands Australia
-
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
-
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
-
Origin Agritech's Three New Corn Varieties Pass Preliminary National Review, Advancing Toward Commercialization
-
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
-
ARKO Petroleum Corp. to Report Third Quarter 2026 Financial Results on November 4, 2026
-
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
-
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
-
Verizon Delivers Another Record-Breaking Quarter with 3Q 2026 Results Driven by Strong Postpaid Phone and Account Additions
-
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
-
VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting Anti-IL-23 Antibody in Canine Chronic Inflammatory Enteropathy
-
GXO and Agility Robotics Expand Partnership to Accelerate Deployment of Humanoids in U.S. Operations
-
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
-
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
-
Centauri Minerals Inc. Begins Trading on OTCQX Best Market
-
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
-
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
-
Heineken N.V. reports the progress of transactions under its current share buyback programme
-
Re-opening of Offer for Subscriptions to Further Applications
-
Changes in Orion Group’s Executive Team as of 1 January 2027
-
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
NOA Lithium Provides Corporate Updates
-
Fury Intersects 14.95 g/t Gold over 4.25 Metres at Eau Claire, Extending High-Grade Mineralization 60 Metres Up-Dip
